Mesenchymal stem cells (MSCs) are multipotent cells that secrete a wide range of anti-inflammatory, immunomodulatory, and regenerative factors. For healthspan, their primary proposed benefit is not replacing old cells, but rather creating a more favorable systemic environment by reducing chronic inflammation (inflammaging) and supporting the body's innate repair mechanisms. This systemic rejuvenation effect is hypothesized to slow the progression of multiple age-related diseases.
Verdict
A high-cost, high-risk frontier with unproven healthspan benefits.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$5000 - $25000
Protocol
- A single high-dose IV infusion (e.g., 100-300 million cells) performed annually or biennially.
- Localized injections into specific joints or tissues as needed for targeted repair.
Flags
- Largely unregulated in the U.S. for anti-aging; clinic quality varies dramatically.
- Risk of infusion reactions, infection, and transmission of communicable disease.
- Long-term risks, including potential for tumorigenesis, are not well understood.
- Efficacy is highly dependent on cell source, dose, viability, and donor age.
- Contraindicated for individuals with active cancer or certain systemic infections.